IMUPEG

Imupeg 6mg Injection contains Pegfilgrastim, an active ingredient classified as a granulocyte colony-stimulating factor (G-CSF) and approved by the FDA. Its primary purpose is to decrease the risk and duration of febrile neutropenia, a condition characterized by fever or infection coinciding with a low white blood cell (WBC) count, particularly in patients receiving bone marrow suppressive chemotherapy drugs. Beyond chemotherapy support, it is also indicated to increase the survival rate in individuals exposed to radiation therapy, which can inflict severe and life-threatening damage to the bone marrow. The medication achieves its effect by acting directly on blood-forming cells, stimulating their multiplication and activating their essential functions.

Pegfilgrastim is a protein synthesized biotechnologically using E. coli bacteria. It is a member of the cytokine family of proteins and closely mimics granulocyte-colony stimulating factor, a natural protein produced by the body. White blood cells (WBCs) are crucial for the body’s immune defense against infection. These cells are particularly vulnerable to the effects of chemotherapy, which can significantly reduce their numbers. A decrease in WBC count compromises the body’s ability to fight bacteria, thereby increasing the risk of infection.

Before initiating treatment with Imupeg 6mg Injection, it is essential to inform your physician if you have or have ever had liver disease, fever or an active infection, kidney problems, heart problems, or a family history of kidney diseases. This injection is contraindicated if you are allergic to pegfilgrastim, filgrastim, or any of its other ingredients. You must immediately report any symptoms of left upper abdominal pain, shoulder pain, or respiratory problems to your doctor, as these could indicate serious side effects. The most common side effects associated with Imupeg 6mg injection are pain experienced in the bones, arms, and legs